• 1
    Harar RP, Kalan A, Kenyon GS. Assessing the reproducibility of nasal spirometry parameters in the measurement of nasal patency. Rhinology 2001;39: 211214.
  • 2
    Ganslmayer M, Spertini F, Rahm F, Terrien MH, Mosimann B, Leimgruber A. Evaluation of acoustic rhinometry in a nasal provocation test with allergen. Allergy 1999;54: 974979.
  • 3
    Wilson AM, Sims EJ, Robb F, Cockburn W, Lipworth BJ. Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology 2003;41: 1620.
  • 4
    Holmstrom M, Scadding GK, Lund VJ, Darby YC. Assessment of nasal obstruction. A comparison between rhinomanometry and nasal inspiratory peak flow. Rhinology 1990;28: 191196.
  • 5
    Jones AS, Viani L, Phillips D, Charters P. The objective assessment of nasal patency. Clin Otolaryngol 1991;16: 206211.
  • 6
    Fairley JW, Durham LH, Ell SR. Correlation of subjective sensation of nasal patency with nasal inspiratory peak flow rate. Clin Otolaryngol 1993;18: 1922.
  • 7
    Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2000;85: 111114.
  • 8
    Morrissey MS, Alun-Jones T, Hill J. The relationship of peak inspiratory airflow to subjective airflow in the nose. Clin Otolaryngol 1990;15: 447451.
  • 9
    Pedersen B, Larsen BB, Dahl R, Hedbys L, Mygind N. Budesonide powder administration for the treatment of grass-pollen-induced allergic rhinitis. Allergy 1994;49: 855860.
  • 10
    Terrien MH, Rahm F, Fellrath JM, Spertini F. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. J Allergy Clin Immunol 1999;103: 10251030.
  • 11
    Penttila M, Poulsen P, Hollingworth K, Holmstrom M. Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin Exp Allergy 2000;30: 94102.
  • 12
    Koskela H, Di Sciascio MB, Anderson SD, Andersson M, Chan HK, Gadalla S et al. Nasal hyperosmolar challenge with a dry powder of mannitol in patients with allergic rhinitis. Evidence for epithelial cell involvement. Clin Exp Allergy 2000;30: 16271636.
  • 13
    Lee DK, Haggart K, Currie GP, Anderson SD, Lipworth BJ. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. Br J Clin Pharmacol 2003;55: 639642.
  • 14
    Ahlstrom-Emanuelsson C, Andersson M, Persson C, Schrewelius C, Greiff L. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin Exp Allergy 2004;34: 731735.
  • 15
    Cook JA, McCombe AW, Jones AS. Laser treatment of rhinitis – 1 year follow-up. Clin Otolaryngol 1993;18: 209211.
  • 16
    Marais J, Murray JA, Marshall I, Douglas N, Martin S. Minimal cross-sectional areas, nasal peak flow and patients’ satisfaction in septoplasty and inferior turbinectomy. Rhinology 1994;32: 145147.
  • 17
    Enberg RN, Ownby DR. Peak nasal inspiratory flow and Wright peak flow: a comparison of their reproducibility. Ann Allergy 1991;67: 371374.
  • 18
    Clarke RW, Jones AS. The limitations of peak nasal flow measurement. Clin Otolaryngol 1994;19: 502504.
  • 19
    Blomgren K, Simola M, Hytonen M, Pitkaranta A. Peak nasal inspiratory and expiratory flow measurements – practical tools in primary care? Rhinology 2003;41: 206210.
  • 20
    Panagou P, Loukides S, Tsipra S, Syrigou K, Anastasakis C, Kalogeropoulos N. Evaluation of nasal patency: comparison of patient and clinician assessments with rhinomanometry. Acta Otolaryngol 1998;118: 847851.
  • 21
    Jose J, Ell SR. The association of subjective nasal patency with peak inspiratory nasal flow in a large healthy population. Clin Otolaryngol 2003;28: 352354.
  • 22
    Peat JK, Salome CM, Woolcock AJ. Longitudinal changes in atopy during a 4-year period: relation to bronchial hyperresponsiveness and respiratory symptoms in a population sample of Australian schoolchildren. J Allergy Clin Immunol 1990;85: 6574.
  • 23
    Meltzer EO. Evaluating rhinitis: clinical, rhinomanometric, and cytologic assessments. J Allergy Clin Immunol 1988;82: 900908.
  • 24
    Xuan W, Marks GB, Toelle BG, Belousova E, Peat JK, Berry G et al. Risk factors for onset and remission of atopy, wheeze, and airway hyperresponsiveness. Thorax 2002;57: 104109.
  • 25
    Yan K, Salome C, Woolcock AJ. Rapid method for measurement of bronchial responsiveness. Thorax 1983;38: 760765.
  • 26
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1: 307310.
  • 27
    Chinn S. The assessment of methods of measurement. Stat Med 1990;9: 351362.
  • 28
    Cho SI, Hauser R, Christiani DC. Reproducibility of nasal peak inspiratory flow among healthy adults: assessment of epidemiologic utility. Chest 1997;112: 15471553.
  • 29
    Bousquet J, Jacot W, Vignola AM, Bachert C, Van Cauwenberge P. Allergic rhinitis: a disease remodeling the upper airways? J Allergy Clin Immunol 2004;113: 4349.